title: Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
authors.affiliation: Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK.
authors.forename: Paolo
authors.initials: P
authors.lastname: Gallipoli
authors.forename: Jon
authors.initials: J
authors.lastname: Stobo
authors.forename: Nicholas
authors.initials: N
authors.lastname: Heaney
authors.forename: Franck E
authors.initials: FE
authors.lastname: Nicolini
authors.forename: Richard
authors.initials: R
authors.lastname: Clark
authors.forename: George
authors.initials: G
authors.lastname: Wilson
authors.forename: Jane
authors.initials: J
authors.lastname: Tighe
authors.forename: Lorna
authors.initials: L
authors.lastname: McLintock
authors.forename: Timothy
authors.initials: T
authors.lastname: Hughes
authors.forename: Franziska
authors.initials: F
authors.lastname: Michor
authors.forename: James
authors.initials: J
authors.lastname: Paul
authors.forename: Mark
authors.initials: M
authors.lastname: Drummond
authors.forename: Tessa L
authors.initials: TL
authors.lastname: Holyoake
mesh_terms: D001549:Benzamides / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002453:Cell Cycle / Q000187:drug effects; D000069439:Dasatinib; D057915:Drug Substitution; D004357:Drug Synergism; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000097:blood; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D020551:Pulse Therapy, Drug; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: C581634:BCR-ABL1 fusion protein, human; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D016179:Granulocyte Colony-Stimulating Factor; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; D000069439:Dasatinib
keywords: BCR-ABL1; chronic myeloid leukaemia; stem cells; therapy; trials